Knowledge in immunology has been advanced by recent research. A new paper presents significant new findings about the protein properdin -- an important part of the immune system. It is a positive ...
Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...
NM5072 is a potential first-in-class monoclonal antibody that selectively blocks properdin, a protein of the complement alternative pathway. The Food and Drug Administration (FDA) has granted Orphan ...
Two functions have been assigned to properdin; stabilization of the alternative convertase, C3bBb, is well accepted, whereas the role of properdin as pattern recognition molecule is controversial. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback